Morbus Crohn der DGVS

1146
Leitlinie
with gastrointestinal diseases. J Clin Gastroenterol 2005; 39:
138–141
632 Langmead L, Rampton DS. Review article: complementary and alternative
therapies for inflammatory bowel disease. Aliment Pharmacol
Ther 2006; 23: 341–349
633 Day AS, Whitten KE, Bohane TD. Use of complementary and alternative
medicines by children and adolescents with inflammatory bowel
disease. J Paediatr Child Health 2004; 40: 681–684
634 Heuschkel R, Afzal N, Wuerth A et al. Complementary medicine use in
children and young adults with inflammatory bowel disease. Am J
Gastroenterol 2002; 97: 382–388
635 McCann LJ, Newell SJ. Survey of paediatric complementary and alternative
medicine use in health and chronic illness. Arch Dis Child
2006; 91: 173–174
636 Ausfeld-Hafter B, Hoffmann S, Seibold F et al. Status of alternative medicine
in Crohn disease and ulcerative colitis patents: a questionnaire
survey. Forsch Komplementarmed Klass Naturheilkd 2005; 12:
134–138
637 Binder V. Prognosis and quality of life in patients with ulcerative colitis
and Crohn’s disease. Int Disabil Stud 1988; 10: 172–174
638 Leong RW, Lawrance IC, Ching JY et al. Knowledge, quality of life, and
use of complementary and alternative medicine and therapies in inflammatory
bowel disease: a comparison of Chinese and Caucasian
patients. Dig Dis Sci 2004; 49: 1672–1676
639 Quattropani C, Ausfeld B, Straumann A et al. Complementary alternative
medicine in patients with inflammatory bowel disease: use and
attitudes. Scand J Gastroenterol 2003; 38: 277–282
640 Joos S, Brinkhaus B, Maluche C et al. Acupuncture and moxibustion in
the treatment of active Crohn’s disease: a randomized controlled
study. Digestion 2004; 69: 131–139
641 Belluzzi A, Brignola C, Campieri M et al. Effect of an enteric-coated
fish-oil preparation on relapses in Crohn’s disease. N Engl J Med
1996; 334: 1557–1560
642 Chawla A, Karl PI, Fisher SE. Effect of N-3 polyunsaturated fatty acid
supplemented diet on neutrophil-mediated ileal permeability and
neutrophil function in the rat. J Am Coll Nutr 1995; 14: 258–263
643 Shoda R, Matsueda K, Yamato S et al. Therapeutic efficacy of N-3 polyunsaturated
fatty acid in experimental Crohn’s disease.
J Gastroenterol 1995; 30: 98–101
644 Yuceyar H, Ozutemiz O, Huseyinov A et al. Is administration of n-3 fatty
acids by mucosal enema protective against trinitrobenzene-induced
colitis in rats? Prostaglandins Leukot Essent Fatty Acids 1999;
61: 339–345
645 Nakazawa A, Hibi T. Is fish oil (n-3 fatty acids) effective for the maintenance
of remission in Crohn’s disease? J Gastroenterol 2000; 35:
173–175
646 Gerhardt H, Seifert F, Buvari P et al. Therapy of active Crohn disease
with Boswellia serrata extract H15. Z Gastroenterol 2001; 39: 11–17
647 Summers RW, Elliott DE, Urban Jr JF et al. Trichuris suis therapy in
Crohn’s disease. Gut 2005; 54: 87–90
648 Kradin RL, Badizadegan K, Auluck P et al. Iatrogenic Trichuris suis infection
in a patient with Crohn disease. Arch Pathol Lab Med 2006;
130: 718–720
649 Kruis W, Schutz E, Fric P et al. Double-blind comparison of an oral
Escherichia coli preparation and mesalazine in maintaining remission
of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853–858
650 Rembacken BJ, Snelling AM, Hawkey PM et al. Non-pathogenic Escherichia
coli versus mesalazine for the treatment of ulcerative colitis: a
randomised trial. Lancet 1999; 354: 635–639
651 Rolfe VE, Fortun PJ, Hawkey CJ et al. Probiotics for maintenance of
remission in Crohn’s disease. Cochrane Database Syst Rev 2006:
CD004826
652 Malchow HA. Crohn’s disease and Escherichia coli. A new approach
in therapy to maintain remission of colonic Crohn’s disease? J Clin
Gastroenterol 1997; 25: 653–658
Hoffmann JC et al. Diagnostik und Therapie… Z Gastroenterol 2008; 46: 1094–1146